Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
2.180
-0.080 (-3.54%)
Jul 3, 2025, 1:00 PM - Market closed
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Richard A. Stewart |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Chief Executive Officer and Executive Director |
| Mark K. Oki CPA | Chief Financial Officer |
| Jerry Wan | Vice President of Finance and Principal Accounting Officer |
| Dr. Anthony Clarke Ph.D. | Chief Scientific Officer |
| Jaime Xinos | Chief Commercial Officer |
| Dr. Mark L. Rubinstein | Head of Medical Affairs |
| Craig Donnelly | Executive Vice President of CMC and Regulatory CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 424B5 | Filing |
| Jun 26, 2025 | 424B5 | Filing |
| Jun 6, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |